Medolife Rx Announces Pre-Clinical Results on Drug Candidate Escozine Showing Efficacy in Eliminating Cell Lines in Ovarian and Bladder Cancer
Medolife Rx, a subsidiary of Quanta (OTC PINK: QNTA), announced successful clinical trial results for its lead drug candidate, Escozine®. The drug completely eradicated in vitro cancer cell lines for bladder and ovarian cancers during a 24-hour study, conducted at a prestigious U.S. research facility. The study confirmed the drug's efficacy, particularly with its polarization technology, which enhances drug potency. Medolife is concurrently pursuing product registration for Escozine® as a COVID-19 therapeutic in the Dominican Republic, aiming for broader clinical applications.
- Escozine® showed complete eradication of bladder and ovarian cancer cell lines in trials.
- The polarization technology used enhances drug efficacy significantly.
- Ongoing clinical studies in the U.S. and Dominican Republic for multiple indications.
- None.
BURBANK, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today clinical trial results conducted on its lead drug candidate Escozine® where the drug eradicated in vitro bladder (SCaBER) and ovarian (OVCAR-3 and IGR-OV1) cancer cell lines when administered for 24 hours.
The study was conducted at one of the most prestigious academic research facilities in the United States. The goal of the study was to assess the viability of human bladder and ovarian cancer cells treated with Escozine®, the Company’s polarized drug candidate derived from a small molecular peptide found in scorpions. It examined the effects of both polarized and non-polarized versions of the drug on the viability of cell walls, finding that only the polarized version had a significant effect on eliminating the cell lines in all three cancers. This highlights not only the potential of Escozine® as a treatment for cancer, but the increased efficacy and bioavailability of the drug through the polarization methodology unique to Medolife Rx. Cell lines are commonly used in in vitro model systems in many drug discovery research programs. They retain most of the genetic properties of the cancer of origin and provide researchers with an indefinite source of biological material for experimental purposes (source). This study was especially significant in that Escozine® eradicated the cell lines completely, furthering the hypothesis that the drug could eliminate cancer cells in humans completely as well.
“We could not be more pleased by the results of this research,” said Medolife CEO Dr. Arthur Mikaelian. “As we progress in our clinical research on Escozine®, where we are initially targeting product registration and approval for treatment of COVID-19, we are conducting ongoing research on its potential therapeutic benefits as a treatment for various other indications, including many types of cancer. In this study, our drug completely eliminated the cell lines of two types of cancer in three samples. These results are not just exciting, they could be the precipice for what could become an effective treatment for one of the largest health issues in the world. Beyond proving the peptides’ ability to eradicate cancer cell lines, the study also showed how effective our polarization technology is on increasing efficacy. With results like these, I could not be more confident in Escozine® as a viable treatment for a variety of health issues and we are so proud to continue to push it through clinical trials around the world.”
The Company is conducting concurrent clinical studies on Escozine® around the world in countries such as the Dominican Republic and the United States. It is seeking product registration in the Dominican Republic for treatment of COVID-19, where it recently announced positive efficacy and safety results on over 500 patients. Additionally, it has filed data on Escozine® with the US Food and Drug Administration (FDA) as a Pre-Investigational New Drug (PIND #150335) as a COVID-19 therapeutic and is hoping to receive a response in short order. Medolife utilizes a patented polarization technology in all of its clinical drug candidates and nutraceutical consumer products that increase the potency of single molecules and complex compounds.
About Medolife Rx
Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products. MedolifeRx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelia who pioneered the unlaying polarization technology that makes the Company’s portfolio of pharmaceutical and nutraceutical products so effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio company. The Company’s lead clinical development programs include Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions which is amplified by the Company’s polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. The Company has completed preclinical safety and efficacy research on Escozine® and is pursuing product registration and drug approval in various countries, including the United States and throughout Latin America.
Through its subsidiary QuantRx, Medolife manufactures and distributes consumer wellness and nutraceutical products in high-impact consumer areas such as pain relief, beauty, and general wellness. QuantRx products are designed using Dr. Mikaelia’s polarization technology which applies advances in quantum biology to increase the potency of active ingredients. Currently, QuantRx supports product formulations in pain management, anti-inflammation, skincare, agriculture, nutritional supplements, and plant-based consumables. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste, and facilitate healthier, more sustainable consumption.
Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Medolife has the opportunity to upend how commercial and pharmaceutical products are made and increase their benefits, while decreasing their chemical concentration.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company's expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management's goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "will," "should," "could," and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Contacts:
Phil Sands
https://ir.quantrx.com/
818-659-8052
Kyle Porter
medolife@cmwmedia.com
858-264-6600
FAQ
What were the results of the Escozine® clinical trial?
What is the significance of the polarization technology in Escozine®?
Is Medolife seeking FDA approval for Escozine®?
What is the next step for Escozine® after these trial results?
How does Escozine® aim to fight cancer?
